In particular, we need to stress that when we discuss information regarding the status of our KRYSTEXXA and marketing efforts, and additional plans related there too, market demand and reimbursement for KRYSTEXXA, our review of the refractory chronic gout or RCG market size, our beliefs with respect to the ability to gain and maintain market acceptance of KRYSTEXXA by physicians, patients, healthcare payers and others in the medical community, our marketing authorization application or MAA pending before the European medicines agency and our intended pursuit of expanded clinical utility for KRYSTEXXA. No inference of overall success of these matters can be implied as they are subject to a number of risks and uncertainties.We encourage you to review our press release dated August 8, 2012 and our company’s filings with the Securities and Exchange Commission including without limitation, our Form 10-Q which will be filed on or before November 9, 2012. Each of these contains important factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Furthermore, the contents of this conference call contains time sensitive information that is accurate only as of the date of this live broadcast August 8, 2012. We undertake no obligation to revise or update our statements to reflect events or circumstances that occur after the date and time of this call. Joining me on the call this morning with prepared remarks are Lou Ferrari, our President and Chief Executive Officer, Ken Bahrt, our Senior Vice President and Chief Medical Officer, and David Gionco, Group Vice President and Chief Accounting Officer. At this time I would like to turn the call over to Lou Ferrari. Louis Ferrari Thank you, Philip, and thank you for joining us this morning. On today’s call, we will discuss our second quarter 2012 financial results and share some important steps we have taken this quarter to ensure the future success of KRYSTEXXA both in the US and globally.